Logo image of GNPX

GENPREX INC (GNPX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GNPX - US3724462037 - Common Stock

3.27 USD
-0.08 (-2.39%)
Last: 12/5/2025, 12:26:54 PM
Fundamental Rating

2

Overall GNPX gets a fundamental rating of 2 out of 10. We evaluated GNPX against 534 industry peers in the Biotechnology industry. GNPX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GNPX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GNPX had negative earnings in the past year.
GNPX had a negative operating cash flow in the past year.
In the past 5 years GNPX always reported negative net income.
GNPX had a negative operating cash flow in each of the past 5 years.
GNPX Yearly Net Income VS EBIT VS OCF VS FCFGNPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -518.59%, GNPX is doing worse than 96.44% of the companies in the same industry.
The Return On Equity of GNPX (-1320.11%) is worse than 81.46% of its industry peers.
Industry RankSector Rank
ROA -518.59%
ROE -1320.11%
ROIC N/A
ROA(3y)-300.81%
ROA(5y)-201.57%
ROE(3y)-614.27%
ROE(5y)-390.18%
ROIC(3y)N/A
ROIC(5y)N/A
GNPX Yearly ROA, ROE, ROICGNPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GNPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNPX Yearly Profit, Operating, Gross MarginsGNPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

GNPX has more shares outstanding than it did 1 year ago.
GNPX has more shares outstanding than it did 5 years ago.
GNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GNPX Yearly Shares OutstandingGNPX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K
GNPX Yearly Total Debt VS Total AssetsGNPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

GNPX has an Altman-Z score of -67.79. This is a bad value and indicates that GNPX is not financially healthy and even has some risk of bankruptcy.
GNPX's Altman-Z score of -67.79 is on the low side compared to the rest of the industry. GNPX is outperformed by 94.19% of its industry peers.
GNPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -67.79
ROIC/WACCN/A
WACCN/A
GNPX Yearly LT Debt VS Equity VS FCFGNPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.83 indicates that GNPX may have some problems paying its short term obligations.
The Current ratio of GNPX (0.83) is worse than 88.95% of its industry peers.
A Quick Ratio of 0.83 indicates that GNPX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.83, GNPX is doing worse than 88.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.83
GNPX Yearly Current Assets VS Current LiabilitesGNPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

GNPX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.49%.
EPS 1Y (TTM)2.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-252.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GNPX will show a very strong growth in Earnings Per Share. The EPS will grow by 36.77% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.94%
EPS Next 2Y36.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GNPX Yearly Revenue VS EstimatesGNPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 50M 100M 150M
GNPX Yearly EPS VS EstimatesGNPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNPX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNPX Price Earnings VS Forward Price EarningsGNPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNPX Per share dataGNPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as GNPX's earnings are expected to grow with 36.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.77%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GNPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENPREX INC

NASDAQ:GNPX (12/5/2025, 12:26:54 PM)

3.27

-0.08 (-2.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners1.74%
Inst Owner Change89.14%
Ins Owners0.21%
Ins Owner Change-0.72%
Market Cap7.42M
Revenue(TTM)N/A
Net Income(TTM)-21.39M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-75.79%
Min EPS beat(2)-189.09%
Max EPS beat(2)37.52%
EPS beat(4)1
Avg EPS beat(4)-55.47%
Min EPS beat(4)-189.09%
Max EPS beat(4)37.52%
EPS beat(8)2
Avg EPS beat(8)-39.29%
EPS beat(12)4
Avg EPS beat(12)-26.12%
EPS beat(16)6
Avg EPS beat(16)-17.15%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4900%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.58
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.38
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-7.55
FCFYN/A
OCF(TTM)-7.55
OCFYN/A
SpS0
BVpS0.71
TBVpS-0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -518.59%
ROE -1320.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-300.81%
ROA(5y)-201.57%
ROE(3y)-614.27%
ROE(5y)-390.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z -67.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)236.4%
Cap/Depr(5y)318.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-252.3%
EPS Next Y85.94%
EPS Next 2Y36.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.68%
OCF growth 3YN/A
OCF growth 5YN/A

GENPREX INC / GNPX FAQ

What is the ChartMill fundamental rating of GENPREX INC (GNPX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to GNPX.


What is the valuation status of GENPREX INC (GNPX) stock?

ChartMill assigns a valuation rating of 1 / 10 to GENPREX INC (GNPX). This can be considered as Overvalued.


How profitable is GENPREX INC (GNPX) stock?

GENPREX INC (GNPX) has a profitability rating of 0 / 10.


Can you provide the financial health for GNPX stock?

The financial health rating of GENPREX INC (GNPX) is 4 / 10.